{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:09:55Z","timestamp":1790662195071,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Immunology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.it.2021.09.001","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T01:16:21Z","timestamp":1631668581000},"page":"956-959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Immune imprinting and SARS-CoV-2 vaccine design"],"prefix":"10.1016","volume":"42","author":[{"given":"Adam K.","family":"Wheatley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon-Xhi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Juno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles P.","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-4891","authenticated-orcid":false,"given":"Stephen J.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.it.2021.09.001_bb0005","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2021.09.001_bb0010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2021.09.001_bb0015","article-title":"The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD","author":"Amanat","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.it.2021.09.001_bb0020","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(21)01290-3","article-title":"Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination","volume":"397","author":"Wall","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.it.2021.09.001_bb0025","article-title":"Preliminary analysis of safety and immunogenicity of a SARS-CoV-2 variant vaccine booster","author":"Wu","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.it.2021.09.001_bb0030","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1084\/jem.106.6.835","article-title":"Predetermination by infection and by vaccination of antibody response to influenza virus vaccines","volume":"106","author":"Davenport","year":"1957","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2021.09.001_bb0035","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(16)00129-8","article-title":"Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies","volume":"16","author":"Belongia","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.it.2021.09.001_bb0040","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1256427","article-title":"Antibody landscapes after influenza virus infection or vaccination","volume":"346","author":"Fonville","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.it.2021.09.001_bb0045","article-title":"SARS-CoV-2 variants: neutralizing antibodies required for protective immunity","author":"Cromer","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.it.2021.09.001_bb0050","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.cell.2021.02.032","article-title":"The antigenic anatomy of SARS-CoV-2 receptor binding domain","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.it.2021.09.001_bb0055","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1038\/s41467-021-23977-1","article-title":"Antibody immunological imprinting on COVID-19 patients","volume":"12","author":"Aydillo","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2021.09.001_bb0060","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41467-021-21665-8","article-title":"Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques","volume":"12","author":"Tan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2021.09.001_bb0065","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1172\/JCI123366","article-title":"Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem","volume":"129","author":"Tan","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.it.2021.09.001_bb0070","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","article-title":"A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial","volume":"27","author":"Nachbagauer","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2021.09.001_bb0075","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat. Med."}],"container-title":["Trends in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490621001770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490621001770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:09:40Z","timestamp":1761462580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471490621001770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1471490621001770"],"URL":"https:\/\/doi.org\/10.1016\/j.it.2021.09.001","relation":{},"ISSN":["1471-4906"],"issn-type":[{"value":"1471-4906","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune imprinting and SARS-CoV-2 vaccine design","name":"articletitle","label":"Article Title"},{"value":"Trends in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.it.2021.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}